|
Dexcom Inc
cgm device dexcom g5 mobile Cgm Device Dexcom G5 Mobile, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/cgm device dexcom g5 mobile/product/Dexcom Inc Average 90 stars, based on 1 article reviews
cgm device dexcom g5 mobile - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
smartphone Smartphone, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/smartphone/product/Dexcom Inc Average 90 stars, based on 1 article reviews
smartphone - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
subcutaneous continuous glucose monitoring dexcom g5 mobile cgms Subcutaneous Continuous Glucose Monitoring Dexcom G5 Mobile Cgms, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/subcutaneous continuous glucose monitoring dexcom g5 mobile cgms/product/Dexcom Inc Average 90 stars, based on 1 article reviews
subcutaneous continuous glucose monitoring dexcom g5 mobile cgms - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
g5(r) mobile cgm G5(R) Mobile Cgm, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/g5(r) mobile cgm/product/Dexcom Inc Average 90 stars, based on 1 article reviews
g5(r) mobile cgm - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
g5 mobile rt-cgm sensor G5 Mobile Rt Cgm Sensor, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/g5 mobile rt-cgm sensor/product/Dexcom Inc Average 90 stars, based on 1 article reviews
g5 mobile rt-cgm sensor - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
standalone cgm plus multiple injections g5 mobile ![]() Standalone Cgm Plus Multiple Injections G5 Mobile, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/standalone cgm plus multiple injections g5 mobile/product/Dexcom Inc Average 90 stars, based on 1 article reviews
standalone cgm plus multiple injections g5 mobile - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
g5 mobile ![]() G5 Mobile, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/g5 mobile/product/Dexcom Inc Average 90 stars, based on 1 article reviews
g5 mobile - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
g4 platinum cgm system ![]() G4 Platinum Cgm System, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/g4 platinum cgm system/product/Dexcom Inc Average 90 stars, based on 1 article reviews
g4 platinum cgm system - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
rt-cgm ![]() Rt Cgm, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/rt-cgm/product/Dexcom Inc Average 90 stars, based on 1 article reviews
rt-cgm - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
standalone cgm dexcom g5 mobile ![]() Standalone Cgm Dexcom G5 Mobile, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/standalone cgm dexcom g5 mobile/product/Dexcom Inc Average 90 stars, based on 1 article reviews
standalone cgm dexcom g5 mobile - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
continuous glucose monitoring system ![]() Continuous Glucose Monitoring System, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/continuous glucose monitoring system/product/Dexcom Inc Average 90 stars, based on 1 article reviews
continuous glucose monitoring system - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
|
Dexcom Inc
dexcom g5 mobile ![]() Dexcom G5 Mobile, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/dexcom g5 mobile/product/Dexcom Inc Average 90 stars, based on 1 article reviews
dexcom g5 mobile - by Bioz Stars,
2026-03
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Disease Interventions and Comparators Evaluated in the Primary Economic Model
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Mean A1C Levels, Changes From Baseline With Continuous Glucose Monitoring a
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Change in A1C From Baseline and Risk Reduction for Diabetes Complications
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Average Annual Per-Patient Cost of Diabetes Complications and Interventions in Ontario
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Cost to Patient of Technologies With Various Levels of Government Funding
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Base Case Analysis
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 1 Results a
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 2 Results
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 3 Results
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 4 Results
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 5 Results
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Number of Current Users of Continuous Glucose Monitoring in Ontario by Age Group
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Manufacturer Projections
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Conservative Projections
Article Snippet: 14 There was no direct evidence that continuous glucose monitoring prevented hospitalizations owing to hypoglycemic events, 25 , 33 , 39 so we did not consider this possibility in our model. table ft1 table-wrap mode="anchored" t5 Table 18: caption a7 Mean Cost ($) a Source First Year Subsequent Years Health State: Diabetes-Related Complications Nephropathy 80 13 O'Brien et al 2003 95 Neuropathy 192 192 O'Brien et al 2003 95 Retinopathy 492 52 O'Brien et al 2003 95 Severe hypoglycemic event (in-patient visit) 3,775 3,775 McQueen et al, 2015 97 Cardiovascular disease 18,682 4,072 O'Reilly et al, 2007 96 Blindness 3,483 2,482 O'Reilly et al, 2007 96 Lower-extremity amputation 43,984 6,024 O'Reilly et al, 2007 96 End-stage renal disease 28,221 12,808 O'Reilly et al, 2007 96 Intervention (Trade Name) Sensor-augmented pump (Dexcom G4 Platinum + Animas Vibe) 11,811 11,811 Dexcom and Animas b Sensor-augmented pump (Dexcom G5 Mobile + Animas Vibe) 11,534 11,534 Dexcom and Animas b Sensor-augmented pump with a low-glucose suspend feature (MiniMed Veo) 9,211 9,211 Medtronic b Standalone CGM plus multiple daily injections (Dexcom G4 Platinum) 10,097 10,097 Dexcom
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Summary of Included Studies
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques: Injection
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Disease Interventions and Comparators Evaluated in the Primary Economic Model
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Mean A1C Levels, Changes From Baseline With Continuous Glucose Monitoring a
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Calculation of Risk Reduction Owing to a Decrease in A1C Level
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Change in A1C From Baseline and Risk Reduction for Diabetes Complications
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Average Annual Per-Patient Cost of Diabetes Complications and Interventions in Ontario
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Costs of Different Diabetes Treatment Technologies a
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Cost to Patient of Technologies With Various Levels of Government Funding
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Base Case Analysis
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 1 Results a
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 2 Results
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 3 Results
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 4 Results
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 5 Results
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Number of Current Users of Continuous Glucose Monitoring in Ontario by Age Group
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Manufacturer Projections
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Conservative Projections
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Continuous Glucose Monitoring Device Cost Reduction Scenarios
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Reasons for Including Four Interventions in the Primary Economic Analysis
Article Snippet: Open in a separate window Annual Cost of Insulin Pump Therapy Table A13: Technology Strips Needles Syringes Total Annual Cost Total Daily Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost Quantity, units Unit Price Cost SAP (Dexcom G4 Platinum + Animas Vibe) 4 $0.73 $2.92 $2.92 $1,066 SAP (Dexcom G5 Mobile + Animas Vibe) 2 $0.73 $1.46 $1.46 $533 SAP with LGS (MiniMed Veo with LGS) 4 $0.73 $2.92 $2.92 $1,066
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Disease Interventions and Comparators Evaluated in the Primary Economic Model
Article Snippet:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Mean A1C Levels, Changes From Baseline With Continuous Glucose Monitoring a
Article Snippet:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Change in A1C From Baseline and Risk Reduction for Diabetes Complications
Article Snippet:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Average Annual Per-Patient Cost of Diabetes Complications and Interventions in Ontario
Article Snippet:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Daily and Annual Costs of Diabetes Treatment Supplies a
Article Snippet:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Annual Costs of Continuous Glucose Monitoring and Insulin Pump a
Article Snippet:
Techniques: Battery
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Cost to Patient of Technologies With Various Levels of Government Funding
Article Snippet:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Base Case Analysis
Article Snippet:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 1 Results a
Article Snippet:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 2 Results
Article Snippet:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 3 Results
Article Snippet:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 4 Results
Article Snippet:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Scenario 5 Results
Article Snippet:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Number of Current Users of Continuous Glucose Monitoring in Ontario by Age Group
Article Snippet:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Manufacturer Projections
Article Snippet:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Estimated Annual Number of Patients Using Continuous Glucose Monitoring in Ontario, Conservative Projections
Article Snippet:
Techniques:
Journal: Ontario Health Technology Assessment Series
Article Title: Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment
doi:
Figure Lengend Snippet: Reasons for Including Four Interventions in the Primary Economic Analysis
Article Snippet:
Techniques: